LUNDEMOSE ANKER MD, PH.D, DSC 4
4 · OSI PHARMACEUTICALS INC · Filed Mar 3, 2010
Insider Transaction Report
Form 4
LUNDEMOSE ANKER MD, PH.D, DSC
Exec. VP & Pres. OSI Prosidion
Transactions
- Exercise/Conversion
Common Stock
2010-03-01$35.10/sh+15,200$533,520→ 46,823 total - Exercise/Conversion
Common Stock
2010-03-01$29.77/sh+13,000$387,010→ 59,823 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-03-01−13,000→ 5,000 totalExercise: $29.77From: 2007-06-13Exp: 2013-06-12→ Common Stock (13,000 underlying) - Sale
Common Stock
2010-03-01$55.20/sh−29,200$1,611,840→ 30,623 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-03-01−15,200→ 0 totalExercise: $35.10From: 2005-02-11Exp: 2014-02-10→ Common Stock (15,200 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 3, 2009.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.32 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]One third of the stock options became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months.
- [F4]25% of the option became exercisable one year after the date of grant and the remainder vests ratably on an annual basis over the succeeding 3 years.
- [F5]Includes only options with the same termination date.